納米刀局部治療前列腺癌

• RELIABLE ABLATION: Electrical pulses to destroy all living cells within the treatment area with no skip lesions
• GENEROUS MARGINS: Increased margin expansion without negatively impacting the rates of erectile function and incontinence in men.
• LESS COLLATERAL DAMAGE: Ability to ablate across the urethra, nerves, and urinary sphincters to ensure treatment of lesions near vital structures while preserving a patient’s quality of life.
• UNMATCHED VERSATILITY: Can treat all segments of the prostate, allowing physicians to build expertise in a single technology to optimize outcomes for patients.
• EASY INTEGRATION: Treatment typically takes one hour and seamlessly integrates into your practice utilizing existing imaging and biopsy skills.
• CONSERVE FUTURE OPTIONS: Procedures can be repeated if necessary and do not interfere with more standard treatments such as surgery or radiotherapy.
• 為局限性前列腺癌提供精確、個人化且可靠的治療替代方案
• 即時可視化和影像指導
• 保護負責泌尿和性功能的組織
• 微創短期門診手術，沒有手術傷口及無需住院
• 幾天後即可恢復正常活動
• 該程序可以重複，並且不排除未來其他治療選擇（如果需要）

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to the NanoKnife© System for prostate tissue ablation, specifically targeting intermediate-risk prostate cancer. This approval was based on the pivotal PRESERVE clinical study, which demonstrated that 84% of patients were free from clinically significant in-field disease 12 months post-procedure. Notably, the study reported strong quality-of-life outcomes, with urinary continence preserved in 95.4% of patients and a minimal decrease in erectile function.

This FDA clearance positions NanoKnife© as a promising, function-preserving treatment option for men with prostate tumors.